Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Ribrag Vincent; Koscielny Serge; Bosq Jacques; Leguay Thibaut; Casasnovas Olivier; Fornecker Luc-Mathieu; Recher Christian; Ghesquieres Herve; Morschhauser Franck; Girault Stephane; Le Gouill Steven; Ojeda-Uribe Mario; Mariette Clara; Cornillon Jerome; Cartron Guillaume; Verge Veronique; Chassagne-Clement Catherine; Dombret Herve; Coiffier Bertrand; Lamy Thierry; Tilly Herve; Salles Gilles

首页> 外文期刊>The Lancet >Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

【24h】

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

机译：Rituximab和剂量茂密的化疗为Burkitt淋巴瘤的成人：随机，受控，开放标签，第3期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm studies suggest that addition of rituximab to these regimens could improve patient outcomes. Our objective was to test this possibility in a randomised trial.

机译：背景技术短期强化化疗是成人患者的伯克特白血病或淋巴瘤的护理标准。单臂研究的结果表明，向这些方案添加Rituximab可以改善患者结果。我们的目标是在随机试验中测试这种可能性。

著录项

来源
《The Lancet》 |2016年第10036期|共10页
作者
Ribrag Vincent; Koscielny Serge; Bosq Jacques; Leguay Thibaut; Casasnovas Olivier; Fornecker Luc-Mathieu; Recher Christian; Ghesquieres Herve; Morschhauser Franck; Girault Stephane; Le Gouill Steven; Ojeda-Uribe Mario; Mariette Clara; Cornillon Jerome; Cartron Guillaume; Verge Veronique; Chassagne-Clement Catherine; Dombret Herve; Coiffier Bertrand; Lamy Thierry; Tilly Herve; Salles Gilles;
展开▼
作者单位

Univ Paris Saclay Dept Med Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Biostat &

Epidemiol Unit Gustave Roussy F-94805 Villejuif France;

Univ Paris Saclay Dept Biopathol Morphol Unit Gustave Roussy F-94805 Villejuif France;

Ctr Hosp Univ Bordeaux Serv Hematol Clin &

Therapie Cellulaire Bordeaux France;

Ctr Hosp Univ Dijon Serv Hematol Clin Dijon France;

Univ Strasbourg Hop Hautepierre Dept Hematol &

Oncol Strasbourg France;

Univ Canc Toulouse Oncopole Serv Hematol Toulouse France;

Univ Lyon 1 Ctr Leon Berard Oncohematol F-69365 Lyon France;

Univ Lille Unite Grp Rech Formes Injectables &

Technol Assoc Serv Malad Sang Lille France;

Ctr Hosp Univ Limoges Hematol Clin &

Therapie Cellulaire Limoges France;

Nantes Univ Hosp Nantes Inst Natl Sante &

Rech Med Ctr Invest Clin 004 Equipe 10 Inst Natl Sante;

Hop Emile Muller Dept Hematol Ctr Competences Thrombot Microangiopathies Mulhouse France;

Grenoble Univ Hosp Dept Haematol Grenoble France;

Inst Canc Lucien Neuwirth Dept Hematol Saint Priest En Jarez France;

Ctr Hosp Univ Montpellier Dept Hematol Ctr Natl Rech Sci Unite Mixte Rech 5235 Montpellier;

Univ Paris Saclay Haematol Unit Gustave Roussy F-94805 Villejuif France;

Ctr Leon Berard Dept Biopathol F-69373 Lyon France;

Ctr Hosp Univ Paris Serv Hematol Clin Grp Hosp St Louis Lariboisiere Fernand Widal France;

Hosp Civils Lyon Hematol Clin Ctr Hosp Lyon Sud Pierre Benite France;

Rennes Univ Hosp Dept Clin Hematol Rennes France;

Univ Rouen Ctr Henri Becquerel Rouen France;

Univ Lyon 1 Hosp Civils Lyon Pierre Benite France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医药、卫生;
关键词

相似文献

外文文献
中文文献
专利

1. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial [J] . Ribrag Vincent, Koscielny Serge, Bosq Jacques, The Lancet . 2016,第10036期

机译：Rituximab和剂量茂密的化疗为Burkitt淋巴瘤的成人：随机，受控，开放标签，第3期试验
2. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: An open-label, randomised, phase 3 trial (DSHNHL 2002-1) [J] . SchmitzN., NickelsenM., ZiepertM., The lancet oncology . 2012,第12期

机译：利妥昔单抗的常规化学疗法（CHOEP-14）或利妥昔单抗的高剂量化学疗法（MegaCHOEP）用于侵袭性B细胞淋巴瘤的年轻高危患者：一项开放标签，随机，3期临床试验（DSHNHL 2002-1）
3. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. [J] . Recher C, Coiffier B, Haioun C, The Lancet . 2011,第9806期

机译：含有ACVBP Plus rituximab的增强化疗与标准CheCh Plus Rituximab用于治疗弥漫性大B细胞淋巴瘤（LNH03-2B）：开放标签随机相3试验。
4. The effect of Virtual Reality in reducing preoperative anxiety in patients prior to arthroscopic knee surgery: A randomised controlled trial [C] . Anitra Robertson, Riaz Khan, Daniel Fick, IEEE International Conference on Serious Games and Applications for Health . 2017

机译：虚拟现实在关节镜膝关节手术前降低患者术前焦虑的作用：一项随机对照试验
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized Multicenter Open-Label Phase 3 Trial [O] . Xueying Li, He Huang, Bing Xu, 2019

机译：新诊断的中国弥漫性大B细胞淋巴瘤患者的剂量密集型利妥昔单抗-CHOP与标准利妥昔单抗-CHOP：一项随机多中心开放标签的3期试验
7. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial [O] . Récher, Christian, Coiffier, Bertrand, Haioun, Corinne, 2011

机译：ACVBP联合利妥昔单抗与标准CHOP联合利妥昔单抗强化化疗治疗弥漫性大B细胞淋巴瘤（LNH03-2B）：一项开放标签的3期随机试验

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

摘要

著录项

相似文献

相关主题

期刊订阅